You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 8,030,291


✉ Email this page to a colleague

« Back to Dashboard


Title:Antisense antiviral compounds and methods for treating a filovirus infection
Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the Ebola virus AUG start site region of VP24; ii) the Ebola virus AUG start site region of VP35; iii) the Marburg virus AUG start site region of VP24; or iv) the Marburg virus AUG start site region of NP.
Inventor(s): Stein; David A. (Corvallis, OR), Iversen; Patrick L. (Corvallis, OR), Bavari; Sina (Frederick, MD), Weller; Dwight D. (Corvallis, OR)
Assignee: AVI BioPharma Inc. (Corvallis, OR) U.S. Army Medical Research and Material Command (Frederick, MD)
Filing Date:Mar 11, 2009
Application Number:12/402,455
Claims:1. A method of treating Ebola virus infection in a subject, comprising: administering to a subject a therapeutically effective amount of an antisense oligomer of 12-40 morpholino subunits linked by phosphorous-containing intersubunit linkages which join a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit, wherein at least 2 and no more than half of the total number of intersubunit linkages are positively charged at physiological pH; and comprising a targeting sequence which forms a heteroduplex with a target sequence of the AUG start-site region of a positive-strand mRNA for Ebola viral protein 24 (VP24); wherein the antisense oligomer inhibits virus production.

2. The method of claim 1, wherein the targeting sequence forms a heteroduplex with the AUG start-site region defined by SEQ ID NO:2.

3. The method of claim 2, wherein the targeting sequence is complementary to at least 12 contiguous bases of the sequence of SEQ ID NO:2.

4. The method of claim 2, wherein the oligomer has 15-25 subunits.

5. The method of claim 2, wherein the heteroduplex has a Tm of dissociation of at least 45.degree. C.

6. The method of claim 1, wherein the morpholino subunits are joined by intersubunit linkages in accordance with the structure: ##STR00003## wherein Y.sub.1.dbd.O, Z.dbd.O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is selected from alkyl alkoxy; thioalkoxy; --NR.sub.2, wherein each R is independently H or lower alkyl; or 1-piperazino.

7. The method of claim 1, wherein the Ebola virus is viral strain Ebola Zaire.

8. The method of claim 1, which further includes administering to the subject a therapeutically effective amount of a second antisense oligomer having the same structure recited in claim 1, but having a targeting sequence which forms a heteroduplex with a target sequence of the AUG start-site region of a positive-strand mRNA for Ebola viral protein 35 (VP35).

9. The method of claim 8, wherein the Ebola viral protein 35 targeting sequence forms a heteroduplex with the AUG start-site region defined by SEQ ID NO: 1.

10. The method of claim 8, wherein the Ebola viral protein 35 targeting sequence is complementary to at least 12 contiguous bases of the sequence of SEQ ID NO:1.

11. The method of claim 1, wherein the targeting sequence comprises the sequence of SEQ ID NO:34.

12. The method of claim 11, wherein the targeting sequence consists of the sequence of SEQ ID NO:34.

13. The method of claim 8, wherein the VP24 targeting sequence consists of the sequence of SEQ ID NO:34, and the VP35 targeting sequence of the second oligomer consists of the sequence of SEQ ID NO:22.

14. The method of claim 13, wherein the antisense oligomers have between 2-8 piperazine-containing intersubunit linkages.

15. The method of claim 13, wherein the oligomer targeted against VP24 and the oligomer targeted against VP35 are administered sequentially.

16. The method of claim 13, wherein the oligomer targeted against VP24 and the oligomer targeted against VP35 are administered concurrently.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.